|Elimination half-life||7–27 hours|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||311.425 g·mol−1|
|3D model (JSmol)|
Femoxetine (INN; tentative brand name Malexil; developmental code name FG-4963) is a drug related to paroxetine that was being developed as an antidepressant by Danish pharmaceutical company Ferrosan in 1975 before acquisition by Novo Nordisk. It acts as a selective serotonin reuptake inhibitor (SSRI). Development was halted to focus attention on paroxetine instead, given femoxetine's inability to be administered as a daily pill.
Both femoxetine and paroxetine were invented in the 1970s by Jorgen Buus-Lassen (Jørgen Anders Christensen name on the patents though). Jorgen Buus-Lassen's name is on the pharmacology paper, however.
After Ferrosan's acquisition, femoxetine died from neglect.[clarification needed]
In a separate patent, Ferrosan stated that Femoxetine could be used as an appetite suppressant. The dosage was 10 times more highly generous than for paroxetine, i.e. 300 - 400mg / day.
Femoxetine still does possess the same stereochemical properties as Nocaine, another agent claimed to have been synthesized using arecoline as the starting alkaloid.
Jørgen Buus Lassen femoxetine.